Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Acthar Stories

2014-04-07 08:29:44

--Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Common Stock They Own-- DUBLIN and ANAHEIM, Calif., April 7, 2014 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction...

2014-02-25 16:29:30

- Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - ANAHEIM, Calif., Feb. 25, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2013. Three Months Ended 12/31/13 Three Months Ended 12/31/12 Percentage Change ------------------------------ ------------------------------ ----------------- Net Sales $242.9...

2013-11-22 08:23:12

-- Company recognized at NephCure annual "Countdown for a Cure" fundraiser ANAHEIM, Calif., Nov. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the company has been recognized with an "Everyday Hero" award from the NephCure Foundation for its "tireless efforts" to advance science and research in the field of nephrology and to also promote educational efforts related to the treatment of proteinuria in patients with kidney disease who are suffering...

2013-11-12 16:26:26

ANAHEIM, Calif., Nov. 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of G. Kelly Martin, President and Chief Executive Officer of Elan Corporation, plc, to Questcor's Board of Directors, bringing the number of directors to eight, seven of whom are independent. Mr. Martin has served as Elan's President, Chief Executive Officer, and a member of its Board of Directors since February 2003. During Mr. Martin's tenure, he led a strategic plan to...

2013-10-29 16:26:02

- Net Sales and EPS Increase Over 65% Compared to Prior Year - ANAHEIM, Calif., Oct. 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the third quarter and nine months ended September 30, 2013. Three Months Ended Three Months Ended 09/30/13 09/30/12 Percentage Change ------------------ ------------------ ----------------- Net Sales $236.3 Million...

2013-10-22 08:31:25

ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). The Company's Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active. ARDS is an acute life-threatening lung condition...

2013-10-10 08:28:38

Dividend Increased to $1.20 per Share on an Annual Basis ANAHEIM, Calif., Oct. 10, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis), reflecting a 5 cent or 20 percent increase over the previous quarter's dividend, and a 50 percent increase year over year. The dividend will be paid on or about October 30, 2013 to shareholders of record at...

2013-09-23 23:34:17

Although Acthar Gel has numerous indications and data suggest that it may be a viable treatment option for resistant nephrotic syndrome, there remains a lack of guidelines on its use. Portland, OR (PRWEB) September 23, 2013 During a recent webinar hosted by AllMed Healthcare Management, Dr. James Wood, board-certified internist and nephrologist, gave an in-depth presentation on the use of Acthar Gel for the treatment of nephrotic syndrome. Although Acthar Gel has numerous indications and...

2013-07-30 16:24:43

- Net Sales and EPS Increase Significantly Over Prior Year - ANAHEIM, Calif., July 30, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter and six months ended June 30, 2013. Three Months Ended Three Months Ended 06/30/13 06/30/12 Percentage Change ------------------- -------------------- ----------------- GAAP Net...

2013-07-24 16:23:57

ANAHEIM, Calif., July 24, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that patient screening will commence in connection with Questcor's Phase 2 Study to explore the safety and tolerability of H.P. Acthar® Gel (repository corticotropin injection) in patients with Amyotrophic Lateral Sclerosis (ALS). ALS -- often referred to as Lou Gehrig's disease -- is a progressive, degenerative disease affecting motor neurons. ALS is a serious debilitating...